Latest Breaking News On - Oncogene subtypes - Page 1 : comparemela.com

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

Patrick fordePost conference perspectivesNon squamous diseaseRet targetedRet fusionOncogene subtypesRet fusion positive nsclcPlatinum doublet chemotherapyTargeted therapyLibretto 431Ntrk fusionsNon squamous lung cancer